Importance Preclinical stroke research has had a remarkably low translational success rate,
and the clinical need for novel neuroprotective therapeutics has gone largely unmet,
especially in light of the severe underuse of thrombolysis in acute ischemic stroke. Objective
In this review, we aim to provide a brief overview of the commonly used stroke models, their
merits and shortcomings, and how these have contributed to translational failures. We
review some recent developments in preclinical stroke, providing examples of how improved …